Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Moleculin Biotech, Inc. logo — Groundbreaking Cancer Therapies

Moleculin Biotech, Inc.

Groundbreaking Cancer Therapies

Founded 2006 United States Houston, United States 22 employees Post-IPO Equity Biotechnology, Pharmaceutical

General Information

Company Name Moleculin Biotech, Inc.
Founded Year 2006
Location United States Houston, United States
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Moleculin Biotech, Inc.. To contact Moleculin Biotech, Inc., visit moleculin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Moleculin Biotech, Inc. compare?

A PDF of Moleculin Biotech, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Moleculin Biotech, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company with a focus on developing a diverse portfolio of drug candidates aimed at treating highly resistant tumors and viruses. The company's lead program, Annamycin, is an innovative anthracycline designed to circumvent multidrug resistance mechanisms with minimal cardiotoxicity. It is currently being developed for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moreover, Moleculin is actively involved in advancing a portfolio of antimetabolites, including WP1122, which holds potential for treating COVID-19 and other viruses, as well as various cancer indications such as brain tumors, pancreatic cancer, and others. The company is also progressing with the development of WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while triggering a natural immune response. This is targeted towards treating brain tumors, pancreatic cancer, and other cancers. Additionally, the company is working on WP1220, an analog to WP1066, intended for the topical treatment of cutaneous T-cell lymphoma. Founded in 2006, Moleculin operates within the Biotechnology and Pharmaceutical industries. The most recent milestone in the company's journey is a Post-IPO Equity investment on 16 August 2024.

Taxonomy: oncology drug development, clinical-stage pharmaceuticals, multidrug resistance mechanisms, anthracycline drug development, immunostimulating drug development, treatment of soft tissue sarcoma, treatment of acute myeloid leukemia, antimetabolite drug development, COVID-19 antiviral drug development, brain tumor treatment, pancreatic cancer treatment, cutaneous T-cell lymphoma treatment, drug development from M.D. Anderson Cancer Center discoveries, STAT3 inhibitors, tumor metabolism targeting

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
16 Aug 2024
Post IPO Equity Undisclosed -
20 Dec 2023
Post IPO Equity Undisclosed -
03 Feb 2021
Debt Financing Undisclosed -
16 May 2014
Venture Series Unknown Undisclosed -
24 Apr 2013
Venture Series Unknown Undisclosed -
22 Aug 2012
Venture Series Unknown Undisclosed -
12 Dec 2011
Venture Series Unknown Undisclosed -
11 Mar 2011

Moleculin Biotech, Inc. Alternatives & Competitors

Moleculin Biotech, Inc. vs
Pacylex Pharmaceuticals, Inc.
Pacylex Pharmaceuticals, Inc. Canada

A new target in cancer care - triggering selective lethality with a new class of drugs.

Grant
9 employees
Biotechnology, Health Care
Moleculin Biotech, Inc. vs
Kura Oncology, Inc.
Kura Oncology, Inc. United States

Our mission is to realize the promise of precision medicines to help patients with cancer lead bette...

315 employees
Biotechnology, Pharmaceutical
Moleculin Biotech, Inc. vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology

FAQ About Moleculin Biotech, Inc.

Groundbreaking Cancer Therapies
Moleculin Biotech, Inc. was founded in 2006.
Moleculin Biotech, Inc. is headquartered in Houston, United States.
Moleculin Biotech, Inc. operates in Biotechnology and Pharmaceutical. Its work centres on oncology drug development, clinical-stage pharmaceuticals, multidrug resistance mechanisms and anthracycline drug development.
Moleculin Biotech, Inc. has approximately 22 employees.
Moleculin Biotech, Inc. has completed 8 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Moleculin Biotech, Inc. include Pacylex Pharmaceuticals, Inc., Kura Oncology, Inc., Prescient Therapeutics, Actinium Pharmaceuticals, Inc., Step Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Moleculin Biotech, Inc. and Pacylex Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Moleculin Biotech, Inc., https://bouncewatch.com/company/moleculin-biotech-inc, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes